Publications by authors named "D Moonka"
Background: Initial analysis of liver transplant biopsies in the INTERLIVER study (ClinicalTrials.gov; unique identifier NCT03193151) using rejection-associated transcripts failed to find an antibody-mediated rejection state (ie, rich in natural killer [NK] cells and with interferon-gamma effects). We recently developed an optimization strategy in lung transplants that isolated an NK cell-enriched rejection-like (NKRL) state that was molecularly distinct from T cell-mediated rejection (TCMR).
View Article and Find Full Text PDFBackground: Hepatitis B virus (HBV) infection causes liver disease, including hepatocellular carcinoma. Controlling viral activity is crucial to reducing complications. Tenofovir may offer benefits over entecavir, but it is unclear if switching from entecavir to tenofovir improves outcomes.
View Article and Find Full Text PDFBackground: We aimed to identify the characteristics of new-onset diabetes after liver transplantation (LT) (NODAT) and investigate its impacts on post-transplant outcomes.
Methods: Adult LT patients between 2014 and 2020 who used tacrolimus as initial immunosuppression and survived 3 months at least were evaluated. Patients who developed NODAT within 3 months after LT were classified as NODAT group.
Article Synopsis
- The study examined the impact of transplant centers' willingness to accept organs from donors after circulatory death (DCD) on patient outcomes in liver transplantation (LT) in the U.S.
- Patients at centers that were very receptive to DCD organs had significantly higher rates of transplants and lower waitlist mortality, especially for those with mid-range MELD-Na scores (6-29).
- Overall, the findings suggest that increasing the use of DCD livers can enhance outcomes for patients waiting for liver transplants, without affecting one-year survival rates post-transplant.
Background: After implementation of the Acuity Circles (AC) allocation policy, use of DCD liver grafts has increased in the United States.
Methods: We evaluated the impact of AC on rates of DCD-liver transplants (LT), their outcomes, and medical costs in a single practice. Adult LT patients were classified into three eras: Era 1 (pre-AC, 1/01/2015-12/31/2017); Era 2 (late pre-AC era, 1/01/2018-02/03/2020); and Era 3 (AC era, 05/10/2020-09/30/2021).